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Abstract: The first case of hyaline vascular type of unicentric Castleman disease (HV-UCD) was
reported more than six decades ago. Since patients with HV-UCD are often asymptomatic and this
condition is generally discovered incidentally on imaging tests, most of the previous reports were
of mediastinal origin detected by chest radiography. In recent years, improved access to imaging
modalities has provided new insights in the diagnosis of this condition. In this study, we reviewed
the detailed clinical and pathological findings of 38 HV-UCD cases (20 males and 18 females, mean
age: 42.8 years). The most common site involved was the abdominal cavity (34.2%), followed by
mediastinum (23.7%) and retroperitoneum (15.8%). In the abdominal cavity, mesenteric origin was the
most common. The mean size of masses was 4.8 cm. Pathologically, thick hyalinized collagen fibers
surrounding large blood vessels and calcification were observed (81.6% and 23.7%, respectively).
Multinucleated giant cells resembling Warthin–Finkeldey cell were also observed in occasional cases
(23.7%). This is a unique paper that summarizes detailed clinical and pathological findings of a
large series of a rare disease. The clinical information presented in this paper is more plausible than
previous views and is useful for accurate diagnosis and understanding of the disease.
Keywords: Castleman disease; hyaline vascular type; unicentric Castleman disease; abdominal
cavity; mediastinum
1. Introduction
Castleman disease (CD) is a rare lymphoproliferative disease, consisting of several
subtypes. Each subtype of CD has a different etiology, clinical manifestations, and histology.
According to the number of enlarged lymph node regions, CD is divided into two major
types: unicentric and multicentric. Unicentric CD (UCD) involves only one lymph node
area and is often asymptomatic or mildly symptomatic, whereas multicentric CD (MCD) is
associated with systemic symptoms and extensive lymph node involvement. UCD is fur-
ther divided into two subtypes based on their histological characteristics: hyaline vascular
(HV) type and plasma cell (PC) type. The HV type is characterized by increased lymphoid
follicles with regressed germinal centers, hyalinized vessels, and hypervascularity within
the interfollicular area. The PC type is characterized by hyperplastic germinal centers with
sheet-like proliferation of plasma cells within the expanded interfollicular area. It has been
reported that most cases of UCD are of the HV type (74.4–91.4%) [1–4].
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CD was first reported in 1954 by Castleman et al. as a case of a 40-year-old man with a
large mediastinal mass which turned out to be lymph node hyperplasia revealing follicles
with hyalinized foci [5]. Subsequently, Castleman reported a series of 13 patients with
enlarged mediastinal lymph nodes having histological features that were similar to those of
currently defined HV-UCD [6]. HV-UCD is considered to be a histologically and clinically
homogeneous entity, lacking systemic symptoms, and is usually curable with excision of
local lesions. Keller and Castleman et al. reported that the most commonly affected sites
in HV-UCD were the mediastinum and lung hilum (90.5%), neck (6.8%), retroperitoneum
(1.4%), axilla (1.4%), and pelvis (1.4%) [1]. In the years when Castleman and Keller reported
the disease, chest radiography was the main diagnostic modality, so the percentages of
mediastinum and lung hilum lesions may have been higher than they actually were.
UCD can occur at any age and occurs equally in men and women, with a mean age at
presentation of approximately 33.8–46.0 years [3,7–10]. In a systematic review of 235 cases
of UCD it was found that the most common sites of involvement included the chest (28.9%),
neck (23.4%), abdomen (20.9%), and retroperitoneum (16.6%) [8]. However, the included
data in this review were from different periods and countries and may differ from the
actual data. Another article, which was a case series, reported that in 43 patients with UCD
(32 HV-CD and 11 PC-CD), the sites found to be commonly involved, in decreasing order
of frequency, were the abdomen (39.5%), neck (23.3%), mediastinum (16.3%), and lung
hilum (7.0%), with limited involvement of lymph nodes in the axilla and groin [4]. There
are no studies to date that have exclusively reported data on HV-UCD. Thus, in the present
study we have carried out a detailed clinical and pathological evaluation of 38 cases of
HV-UCD and presented a comprehensive description of the obtained findings.
2. Materials and Methods
2.1. Patient Selection
The study protocol was approved by the Institutional Review Board of Okayama
University, Okayama, Japan. We used opt-out to obtain consent for participation in this
study. A total of 38 Japanese patients with HV-UCD were retrospectively identified and
included in this study. All cases were retrieved from surgical pathology consultation files
from the Department of Pathology of Okayama university between the years 2001–2020. In
all cases, the lesions were localized in a single region. Immunostaining for CD20, CD3 and
Ki-67 was performed in all these patients, and lymphoma was ruled out. Human herpes
virus type 8 infectious status was not examined in this study population. None of the
patients had autoimmune diseases or used corticosteroids or immunosuppressants. Other
diseases with histopathological features overlapping with those of UCD were also excluded
according to the guidelines of Frits et al. [11]. All the included patients had undergone
surgery for total resection of the lesion.
2.2. Diagnosis of HV-UCD
The diagnosis of HV-UCD was made in postoperative surgical specimens and di-
agnosed by several pathologists at the department of pathology case review meeting.
The pathological diagnosis of CD was established according to Keller’s criteria [1]. All
cases satisfied the following histologic criteria: (1) proliferation of follicle-like structures,
(2) regressed germinal center with radially penetrating capillaries, (3) extensive capillary
proliferation with obliteration of lymphatic sinuses, and (4) perivascular hyalinization in
both the germinal center and interfollicular area.
3. Results
3.1. Clinical Findings
The demographic and clinical characteristics of HV UCD patients are summarized in
Tables 1 and 2 provides detailed clinical information for all cases.
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Table 1. Demographic and Clinical Features of Patients with HV-type UCD.
n = 38
Age (year)
mean ± SD (range) 42.8 ± 17.8 (12–76)
<50, n (%) 24 (63.2)




Local pain 2 (5.3)
Awareness of the mass 7 (18.4)
Abdominal discomfort 1 (2.6)
Paraneoplastic pemphigus 1 (2.6)
Site, n (%)
Abdominal cavity 13 (34.2)
Mesentery 7 (18.4)
Omentum 2 (5.3)
Lesser omentum 1 (2.6)








Lymph node 5 (13.2)
Axillary Lymph node 2 (5.3)
Cervical Lymph node 2 (5.3)
Hilar Lymph node 1 (2.6)
Soft tissue 4 (10.5)
Kidney 1 (2.6)
Tumor diameter (cm) mean ± SD (range)
Total 4.8 ± 2.2 (1.7–11.0)
Abdominal 4.1 ± 1.4 (2.0–6.5)
Retroperitoneum 5.8 ± 3.0 (3.0–11.0)
Mediastinum 4.8 ± 2.3 (1.7–9.0)
Soft tissue 4.3 ± 1.2 (3.0–5.0)
Laboratory findings (mean ± SD)
WBC (/µL) (n = 22) 5467 ± 1663
Hb (g/dL) male (n = 13) 15.0 ± 1.0
Hb (g/dL) female (n = 9) 13.4 ± 1.4
Plt (×104/µL) (n = 22) 26.8 ± 7.1
TP(g/dL) (n = 21) 7.3 ± 0.4
Alb (g/dL) (n = 21) 4.4 ± 0.5
CRP (mg/dL) (n = 20) 0.2 ± 0.2
LDH (U/L) (n = 22) 184 ± 53.5
Abbreviations: SD; standard deviation, WBC; white blood cell, Hb: hemoglobin, Plt; platelet, TP; Total protein,
Alb; albumin, CRP; C-reactive protein, LDH; Lactate Dehydrogenase. Normal ranges: WBC 3900–9800/µL,
Hb 13.4–17.6 g/dL (male) 11.3–15.2 g/dL (female), Plt 12.7–35.6 × 104/µL, TP 6.7–8.3 g/dL, Alb 3.7–5.2 g/dL,
CRP 0.00–0.30 mg/dl, LDH 119–229 U/L.
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Table 2. Detailed of clinical findings.






1 29 M None Retroperitoneum None Lumbar X-ray forlumbar sprain 3.6 —

















5 38 F None Mediastinum(middle) None
CT for high serum
SCC antigen 6.0 Teratoma, Thymoma










6.5 GIST, Neurogenictumor, UCD








9 16 M None Mediastinum(posterior) None
School screening








None Follow-up CT forrectal cancer 2.5 Cancer dissemination























14 39 F None Abdominal mass(omentum) None
Abdominal US for
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Table 2. Cont.















CT for LN swelling 7.7 Lymphoma




None CT for thoroughmedical checkup 2.0
RCC, Leiomyoma,
Angiomyolipoma






2.3 UCD, NET, GIST, SFT







CT and MRI for
subcutaneous mass 4,0 Sarcoma









None Abdominal CT forgenital bleeding 3.4 UCD
29 53 M None Abdominal(omentum) None
CT for thorough
medical checkup 5.8 —









genital bleeding 4.0 —













34 14 M None






subcutaneous mass 3.0 Soft tissue tumor







subcutaneous mass 5.0 —





37 28 M None Hilum LN None Screening chestX-ray 3.6
UCD, SFT,
Carcinoid tumor
38 65 F None Cervical LN None CT for thoroughmedical checkup 1.6
IgG4-related disease,
Lymphoma
Abbreviations: PMH; past medical history, DM; diabetes mellitus, LN; lymph node, SCC; squamous cell carcinoma, US; ultrasonography, CT;
computed tomography, MRI; magnetic resonance imaging, UCD; unicentric Castleman disease, GIST; gastrointestinal tumor, SFT; solitary
fibrous tumor, RCC; renal cell carcinoma, NET; neuroendocrine tumor, PNP; paraneoplastic pemphigus, BO; bronchiolitis obliterans.
Of the 38 included patients, 20 were men and 18 were women with a mean age of
42.8 years (range, 12–76 years) at the time of diagnosis. Majority (24/38, 63.2%) of the
patients were aged <50 years. Comorbidities included hyperlipidemia (3/38, 7.9%), asthma
(2/38, 5.3%), and type 2 diabetes mellitus (1/38, 2.6%), as well as a history of malignant or
infectious diseases that led to implementation of imaging studies for the diagnosis.
Patients who presented with subcutaneous masses or superficial lymph node swellings
were aware of the mass or had localized pain, while most patients with lesions involving
the deeper sites were asymptomatic. However, a few patients with retroperitoneal or pelvic
masses complained of abdominal discomfort or back pain (2/38, 5.3%). Notably, in one
case, the presence of paraneoplastic pemphigus led to the discovery of a lymph node lesion.
The patient had oral erosions for two years prior to the diagnosis of HV-UCD. Subsequently,
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shortness of breath and coughing appeared. After a thorough examination, the patient
was diagnosed with paraneoplastic pemphigus (PNP) and bronchiolitis obliterans (BO).
Plasmapheresis and oral corticosteroids in a dose of 0.5 mg/kg were started along with
resection of the lesion of HV-UCD, resulting in improvement of mucosal symptoms. The
mucosal symptoms relapsed once during the tapering of steroids, but the PNP has been
in remission since then with the maintenance dose of oral corticosteroids monotherapy
(0.1 mg/kg). The BO has yet to go into remission but is well controlled with oral corticos-
teroids and has not had rapid exacerbations. The patient is still alive 20 years after the
diagnosis of HV-UCD.
In 13 patients, lesions were incidentally found during diagnostic investigations for other
comorbidities such as malignancy, gynecologic disease, or infection (13/38, 34.2%), whereas
some cases were discovered as incidental findings during routine checkups (9/38, 23.7%).
The most common site of involvement was the abdominal cavity (13/38, 34.2%), with
lesions of mostly mesenteric origin (7/13). This was followed by mediastinum (9/38,
23.7%), retroperitoneum (6/38, 15.8%), subcutaneous tissues of the back, buttocks, or
extremities (4/38, 10.5%), axillary lymph nodes (2/38, 5.3%), cervical lymph nodes (2/38,
5.3%), hilar lymph nodes (1/28, 2.6%), and kidney (2.6%). The kidney mass was found
within the parenchyma of the lower pole.
18F-fluorodeoxyglucose positron emission tomography-computed tomography (18F-
FDG PET-CT) results could be obtained for the following seven patients: patient number
2, 7, 8, 25, 27, 28, 37. The mean maximum standardized uptake value (SUV-max) was 4.8
(range 2.5–9.1). In all these patients, the identical lesions that had 18F-FDG accumulation
were surgically resected. There were no other sites showing 18F-FDG accumulation other
than the resected lesions.
Preoperative differential diagnoses besides HV-UCD included gastrointestinal stro-
mal tumor, solitary fibrous tumor, neurogenic tumor, lymphoma, metastatic carcinoma,
and sarcoma in the abdominal cavity; paraganglioma, lymphoma, and sarcoma, in the
retroperitoneum; thymoma, thymic carcinoma, neurogenic tumor, embryonal carcinoma,
teratoma, and lymphoma, in the mediastinum.
The mean maximum diameter of the evaluated masses was 4.8 cm (range 1.7–11.0 cm). The
mean diameters of the lesions in the abdominal cavity, retroperitoneum, and mediastinum
were 4.1 cm (range 2.0–6.5), 5.8 cm (range 3.0–11.0), and 4.8 cm (range 1.7–9.0), respec-
tively. All patients underwent total resection of the lesions, and none of them received
chemotherapy or radiotherapy. Clinical follow-up was carried out in 17 cases, and no
recurrences were reported. The mean follow-up period was 72.7 months. There were no
abnormal hematological findings such as anemia, increased inflammatory markers, or
hypergammaglobulinemia in any of the patients.
3.2. Histological Findings
Representative histological findings of the included cases are presented in Figure 1.
HV-UCD is characterized by one or more atrophic germinal centers with small lymphocytes
present concentrically around them. Radially penetrating capillaries or branched hyalinized
vessels are often observed in atrophic germinal centers. In the interfollicular area, extensive
capillary proliferation was observed. Plasmacytes and eosinophils were found sporadically,
and no aggregation or sheet-like proliferation of plasma cells was observed. Altered follicle
structure with expanded mantle zone (progressive transformation of germinal center-like
pattern) was observed in four cases (Figure 2).
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Figure 1. Representative histological findings in hyaline vascular type unicentric Castleman disease.
(A) (H&E); hyperplasia of follicular structures. (B) (H&E); atrophic germinal center with penetrating
hyalinized blood vessels and concentric mantle zones, which is a so-called “lollipop” appearance.
(C) (H&E); extensive capillary proliferation in the interfollicular area was also observed. (D) (CD21);
CD21 staining highlights prominent follicular dendritic cell meshwork.
Figure 2. Progressive transformation of germinal centers-like structure. (A,B) (H&E); altered follicle
structures with expanded mantle zones are shown.
The degree of hyalinization was variable. Thick hyalinized collagen fibers were seen
in the interfollicular area surrounding large blood vessels while broad hyalinized collagen
fibers spreading throughout the lesion were also often observed (31/38, 81.6% and 15/38,
39.5%, respectively) (Figure 3). This broad hyalinized area was associated with calcification
in nine patients (23.7%).
In the follicular and interfollicular area, multinucleated giant cells resembling Warthin–
Finkeldey cell were observed in occasional cases (9/38, 23.7%) (Figure 4). These multin-
ucleated giant cells were observed in the germinal center and interfollicular area. These
multinucleated cells were positive for CD21 and CXCL13 in the cytoplasm, and negative for
CD23, CD20, CD3, CD43, CD30, and CD68. In CD21 staining, the cytoplasmic border was
indistinct, and the cells appeared to trap the surrounding small lymphocytes. These small
lymphocytes surrounding the multinucleated cell were negative for CD43 and positive for
CD20, suggesting B cells.
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Figure 3. Hyalinization and calcification in hyaline vascular type unicentric Castleman disease.
(A) (H&E); broad hyalinized collagen fibers spreading throughout the lesion. (B) (H&E); thick hyalinized
collagen fibers surrounding large blood vessels. (C) (H&E); calcium deposition in hyalinized area.
Figure 4. Multinucleated giant cells resembling Warthin–Finkeldey cell (indicated by an arrow-
head). (A,B) (H&E); Multinucleated giant cells resembling Warthin–Finkeldey cell were observed
in germinal center area and interfollicular area. (C,D) (H&E); the morphology of multinucleated
giant cells showed some variation, but the nuclei with a single distinct nucleolus were arranged in
a grape-like cluster. (E) (CD21); the cytoplasm of multinucleated giant cells was positive for CD21.
The cytoplasmic border was indistinct with lymphocytes entrapment. (F) (CXCL13); CXCL13 was
positive in the cytoplasm of multinucleated giant cells. (G) (CD43) and (H) (CD20); small lympho-
cytes entrapped in the cytoplasm of multinucleated giant cells are negative for CD43 and positive
for CD20.
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4. Discussion
In this study, we present detailed clinical data and pathological findings of 38 his-
tologically well-defined HV-UCD cases. This is a unique study considering the fact that
exclusive reports on HV-UCD are scarce in the existing literature and as such detailed
evaluation of multiple cases of HV-UCD will add immensely to the current knowledge of
this entity.
4.1. Clinical Characteristics
Data on age, sex, and symptoms were similar to those in the previous reports [3,7–10].
As discussed earlier, HV-UCD has been thought to occur predominantly in the mediastinal
region, but our study revealed that HV-UCD most common involvement site was in the
abdominal cavity. Given the advances in imaging modalities [12], the results of the present
study may be closer to the actual lesion distribution of HV-UCD.
While malignant tumors (rectal cancer and uterine cancer), benign tumors (uterine
leiomyoma, ovarian benign serous tumor, and mature teratoma of the mediastinum), and
inflammatory diseases (ascending colon diverticulitis and ischemic enteritis) were present
in nine patients, the relationship between these diseases and HV-UCD has been unclear. In
severe infections and autoimmune diseases, the adjacent lymph nodes may show reactions
such as follicular hyperplasia, hypervascularization, and plasma cell proliferation in the
enlarged interfollicular area. However, the histological features of HV-UCD, such as
hyalinization of the blood vessels and atrophy of the germinal center, are uncommon in
these diseases, so histological differentiation is not considered to be a problem. The patients
included in this study did not have any underlying disease that could exhibit histology
similar to HV-UCD.
One of our patients had PNP and BO in association with CD. A previous report has
shown that CD is one of the most common causes of tumor-associated pemphigus, along
with non-Hodgkin’s lymphoma and other hematologic tumors [13,14]. BO is a serious
manifestation of PNP and is one of the leading causes of mortality. Although the frequency
varies among reports, it has been reported that about 30% of PNP is associated with
BO [15,16], with a higher frequency in children and adolescents with CD. In one report, the
frequency of bronchiolitis obliterans was 93% in a series of 28 patients with PNP, which
included 15 children and adolescents with CD [17]. Since autoantibodies produced by
tumor cells are responsible for the pathogenesis of mucocutaneous lesions, removal of solid
tumors and remission of hematologic tumors by chemotherapy are critical for improvement
of PNP [18]. Complete resection of localized Castleman’s disease may result in significant
improvement or complete remission of the condition [19]. However, it takes several years
after surgery to achieve remission, and during that time, serious complications such as
respiratory failure can occur.
In this study, four cases of subcutaneous masses, which are considered rare, were also
included [20]. One of this was a mass arising in the kidney, which is an extremely rare
location for HV-UCD lesions [21]. Other unusual sites such as the orbits, nasopharynx,
lungs, and spleen have also been reported in literature [22–25]. Thus, it is important to
keep in mind that these unusual sites might also be involved, while making a diagnosis of
HV-UCD.
There have been several reports of 18F-FDG avid UCD lesions [3,4,26–29]. In these
reports, FDG uptake was moderately increased in UCD, and SUVs were generally less than
those observed in lymphoma. Our results were also consistent with this.
4.2. Histological Characteristics
HV-UCD is preferably diagnosed by excisional biopsy of the enlarged lymph nodes.
Although there are several diseases that show CD-like histopathological features such as
unusual morphological variants of follicular lymphoma, angioimmunoblastic T-cell lym-
phoma, these usually present with generalized lymphadenopathy and are rarely confused
with UCD [11].
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The finding of altered follicular structure with expanded mantle zone, as shown in
Figure 2, may also be seen as a progressive transformation of germinal centers. In the
present study, calcification was found in 23.7% of lesions. Various patterns of calcification
have been reported within the lesion in past reports [3,30–33]. Calcification and extensive
hyalinization may indicate that the lesion is indolent.
In this study, multinucleated giant cells resembling Warthin–Finkeldey cells were
observed in the germinal center or interfollicular area in nine cases. Although Warthin–
Finkeldey cells are commonly seen in Kimura disease, a rare chronic inflammatory disease
with unclear etiology, these are not unique to Kimura disease and are also observed in
measles and a variety of reactive or neoplastic lymphoid conditions. In the present study,
these multinucleated giant cells were positive for the follicular dendritic cell (FDC) markers
such as CD21 and CXCL13, and were considered to be identical to those referred to as
dysplastic FDCs in previous reports [34–38]. It has been reported that FDC sarcoma may
occur in lymph nodes in the same region subsequently to UCD [37,38], suggesting that
dysplastic FDCs may be a primary driver of UCD pathogenesis.
4.3. Future Prospects
The etiology of HV-UCD has been unclear since the disease was first reported over
60 years ago. Although the lineage of cells responsible for the pathogenesis of UCD has not
been identified, several studies have hypothesized that a neoplastic stromal cell population
may be the precursor of UCD [39–44]. Recently, Li et al. found recurrent PDGFRB N666S
mutations in UCD cases, and they also investigated the cell of origin using BaseScope,
a mutation-specific RNA in situ hybridization assay. Their results suggested that the
PDGFRB N666S mutations were confined to non-hematopoietic stromal cells in UCD, and
it is likely that they play an important role in UCD pathogenesis [45].
With this latest body of evidence, we have a better understanding of the pathogenesis
of HV-UCD. However, owing to the rarity of the disease, it is necessary to accumulate
further evidence with a focus on genetic analysis in the future.
5. Conclusions
In conclusion, our study provides up-to-date clinical and pathological findings of patients
with HV-UCD. The detailed clinical information presented in this paper is more plausible
than previously thought and is useful for accurate diagnosis and understanding of the disease.
Comprehensive genetic analysis of histologically well-defined HV-UCD patients is required
as a next step in this area of study to clarify the pathogenesis of the disease.
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